Clinical Trials · NCT04384081
A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 37
- Start date
- Jun 2020
- Locations
- 1 site, Japan
- Primary endpoint
- Cumulative percentage (%) of subjects withdrawn from up-titration by dose escalation scheme.